CN112771214B - 用于选择新表位的方法 - Google Patents

用于选择新表位的方法 Download PDF

Info

Publication number
CN112771214B
CN112771214B CN201980063254.9A CN201980063254A CN112771214B CN 112771214 B CN112771214 B CN 112771214B CN 201980063254 A CN201980063254 A CN 201980063254A CN 112771214 B CN112771214 B CN 112771214B
Authority
CN
China
Prior art keywords
mhc
epitope
epitopes
neoepitope
neo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980063254.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN112771214A (zh
Inventor
莫妮卡·塞克利亚
卡罗琳·施杰田纳
阿涅特·布伦斯维克·弗雷德里克森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Necord Therapeutics Ltd
Original Assignee
Necord Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Necord Therapeutics Ltd filed Critical Necord Therapeutics Ltd
Publication of CN112771214A publication Critical patent/CN112771214A/zh
Application granted granted Critical
Publication of CN112771214B publication Critical patent/CN112771214B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30Detection of binding sites or motifs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201980063254.9A 2018-09-27 2019-09-27 用于选择新表位的方法 Active CN112771214B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18197172.2 2018-09-27
EP18197172 2018-09-27
PCT/EP2019/076210 WO2020065023A1 (en) 2018-09-27 2019-09-27 Method for selecting neoepitopes

Publications (2)

Publication Number Publication Date
CN112771214A CN112771214A (zh) 2021-05-07
CN112771214B true CN112771214B (zh) 2025-06-13

Family

ID=63794302

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980063254.9A Active CN112771214B (zh) 2018-09-27 2019-09-27 用于选择新表位的方法

Country Status (12)

Country Link
US (1) US12462898B2 (https=)
EP (1) EP3856957A1 (https=)
JP (1) JP7585195B2 (https=)
KR (1) KR102902460B1 (https=)
CN (1) CN112771214B (https=)
AU (1) AU2019346023B2 (https=)
BR (1) BR112021005702A8 (https=)
CA (1) CA3111903A1 (https=)
IL (1) IL281771B2 (https=)
MX (1) MX2021003654A (https=)
SG (1) SG11202101965QA (https=)
WO (1) WO2020065023A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020221783A1 (en) * 2019-04-29 2020-11-05 Vaccibody As Methods for pre-selection of neoepitopes
US20230197192A1 (en) * 2020-11-06 2023-06-22 Amazon Technologies, Inc. Selecting neoantigens for personalized cancer vaccine
GB202102606D0 (en) * 2021-02-24 2021-04-07 Univ Oxford Innovation Ltd Treatment of ovarian cancer minimal residual disease
IL305777A (en) 2021-03-26 2023-11-01 Nykode Therapeutics ASA Medical combination for cancer treatment
WO2022238420A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Co-expression of constructs and immunostimulatory compounds
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
WO2023244997A1 (en) * 2022-06-13 2023-12-21 The University Of North Carolina At Chapel Hill Compositions and methods for inducing anticancer immunity
EP4608436A1 (en) 2022-10-25 2025-09-03 Nykode Therapeutics ASA Constructs and their use
KR102857635B1 (ko) * 2022-11-08 2025-09-10 인바이츠지노믹스 주식회사 면역원성이 높은 유사체를 디자인하는 방법 및 이를 이용한 장치
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides
WO2024216073A1 (en) * 2023-04-14 2024-10-17 The Trustees Of Columbia University In The City Of New York Engineered microbes comprising tumor neoantigen vectors for cancer immunotherapy
US20250232833A1 (en) * 2024-01-13 2025-07-17 Noergaard Anders Kaare Cyclin D1 Based Cancer Vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108351916A (zh) * 2015-07-14 2018-07-31 个人基因组诊断公司 新生抗原分析
CN108513593A (zh) * 2015-04-23 2018-09-07 南托米克斯有限责任公司 癌症新表位

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012029066A2 (pt) 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
HRP20211595T1 (hr) 2011-05-24 2022-01-21 BioNTech SE Individualizirana cjepiva protiv raka
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
CN118750591A (zh) 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
JP6558699B2 (ja) 2013-10-01 2019-08-14 国立大学法人三重大学 抗原提示を促進するエピトープ間配列を含むt細胞誘導ワクチン
US11186640B2 (en) 2014-07-31 2021-11-30 The University Of Western Australia Method for the identification of immunotherapy-drug combinations using a network approach
EP3193892A4 (en) 2014-09-14 2018-09-12 Washington University Personalized cancer vaccines and methods therefor
US10317402B2 (en) 2014-12-03 2019-06-11 Verik Bio, Inc. Identification, selection and use of high curative potential T cell epitopes
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
SG10201912485PA (en) * 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
WO2018136664A1 (en) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108513593A (zh) * 2015-04-23 2018-09-07 南托米克斯有限责任公司 癌症新表位
CN108351916A (zh) * 2015-07-14 2018-07-31 个人基因组诊断公司 新生抗原分析

Also Published As

Publication number Publication date
JP2022502416A (ja) 2022-01-11
BR112021005702A2 (pt) 2021-06-22
IL281771B1 (en) 2025-04-01
MX2021003654A (es) 2021-05-28
AU2019346023A1 (en) 2021-03-25
BR112021005702A8 (pt) 2022-11-08
US12462898B2 (en) 2025-11-04
WO2020065023A1 (en) 2020-04-02
US20210388438A1 (en) 2021-12-16
JP7585195B2 (ja) 2024-11-18
CA3111903A1 (en) 2020-04-02
CN112771214A (zh) 2021-05-07
KR102902460B1 (ko) 2025-12-19
EP3856957A1 (en) 2021-08-04
IL281771B2 (en) 2025-08-01
KR20210065171A (ko) 2021-06-03
AU2019346023B2 (en) 2024-12-12
SG11202101965QA (en) 2021-04-29
IL281771A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
CN112771214B (zh) 用于选择新表位的方法
JP7530455B2 (ja) 新生抗原の特定、製造、及び使用
JP7651623B2 (ja) 新生抗原の特定、製造、及び使用
TWI909205B (zh) 利用熱點識別新抗原之方法及電腦系統
EP2872653B1 (en) Personalized cancer vaccines and adoptive immune cell therapies
TWI672503B (zh) 致免疫性之癌症特異抗原決定位的排名系統
KR20230042048A (ko) 펩타이드 결합, 제시, 및 면역원성을 예측하기 위한 어텐션-기반 신경망
US20170212984A1 (en) Neoantigen Identification, Manufacture, and Use
TW202000693A (zh) 利用泛對偶基因(pan-allele)模型之新抗原鑑別
CN113711239A (zh) 利用ii类mhc模型鉴别新抗原
CA3217623A1 (en) Compositions and method for optimized peptide vaccines using residue optimization
WO2020221783A1 (en) Methods for pre-selection of neoepitopes
JP2021503897A (ja) 新生抗原のためのジャンクションエピトープ提示の低減
Asadollahi et al. Development of a multi-neoepitope vaccine targeting non-small cell lung cancer through reverse vaccinology and bioinformatics approaches
RU2826184C2 (ru) Способ отбора неоэпитопов
Ghesmati Immunoinformatics based designing of a multi-epitope peptide vaccine candidate against prostate cancer
HK40013532B (zh) 致免疫性的癌症特异抗原决定位的排名系统

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Oslo, Norway

Applicant after: Necord treatment Co.,Ltd.

Address before: Oslo, Norway

Applicant before: VACCIBODY A/S

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Oslo, Norway

Applicant after: necord therapeutics Ltd.

Address before: Oslo, Norway

Applicant before: Necord treatment Co.,Ltd.

GR01 Patent grant
GR01 Patent grant